Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 407

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Preoperative chemotherapy for women with operable breast cancer

Open access
van der Hage, Jos H, van de Velde, Cornelis JH, Mieog, Sven JSD, Charehbili, Ayoub·2007·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Currently, preoperative chemotherapy is the standard of care in locally advanced breast cancer to achieve local tumour downsizing in order to make surgery possible. Since the early 1980s, the role of preoperative chemotherapy in early stage (or operable) breast cancer has been the subject of study. Potential advantages are early introduction of systemic therapy, determination of chemosensitivity, reduction of tumour volume and downstaging of surgical requirement. Concerns exist about local control after downsized surgery and the delay of local treatment in patients with tumours resistant to chemotherapy. OBJECTIVES: To assess the effectiveness of preoperative chemotherapy in women with operable breast cancer when compared to postoperative chemotherapy. SEARCH STRATEGY: The Specialised Register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 4th of August 2005. SELECTION CRITERIA: Randomised trials comparing preoperative chemotherapy with postoperative in women with operable breast cancer. DATA COLLECTION AND ANALYSIS: Studies were assessed for eligibility and quality, and data were extracted by two independent review authors. Hazard ratios were derived for time-to-event outcomes directly or indirectly using the methods described by Parmar. Relative risks were derived for dichotomous outcomes. Meta-analyses were performed using fixed effect model. MAIN RESULTS: We identified 14 eligible studies which randomised a total of 5,500 women. Median follow-up ranged from 18 to 124 months. Eight studies described a satisfactory method of randomisation.Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4). AUTHORS' CONCLUSIONS: This review suggests safe application of preoperative chemotherapy in the treatment of women with early stage breast cancer in order to down-stage surgical requirement, to evaluate chemosensitivity and to facilitate translational research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005002.pub2

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 29

  1. Mauriac, 1999, Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS), Annals of Oncology, 10, 47, 10.1023/A:1008337009350 · doi:10.1023/a:1008337009350
  2. Gianni, 2005, European cooperative trial in operable breast cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF), Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 23, Abstract 513
  3. Forouhi, 1995, Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer, British Journal of Surgery, 82, 79, 10.1002/bjs.1800820127 · doi:10.1002/bjs.1800820127
  4. Scholl, 1991, Neoadjuvant chemotherapy in operable breast cancer, European Journal of Cancer, 27, 1668, 10.1016/0277-5379(91)90442-G · doi:10.1016/0277-5379(91)90442-g
  5. Enomoto K Ikeda T Matsui A Kitajima M Koh J Neoadjuvant therapy in stage II with T>=4CM and stage III breast cancer 6th International Conference Adjuvant therapy for Primary Breast Cancer St Gallen 1998 P73 · doi:10.1016/s0959-8049(97)89290-8
  6. Ostapenko V Pipiriene T Valuckas K Primary chemotherapy in conservative treatment of stage II breast cancer In 6th International Conference Adjuvant therapy for Primary Breast Cancer St Gallen 1998 Abstract P78 · doi:10.1016/s0959-8049(97)89295-7
  7. Gazet, 2001, Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy, Annals of Oncology, 12, 685, 10.1023/A:1011115107615 · doi:10.1023/a:1011115107615
  8. Makris, 1998, A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Annals of Oncology, 9, 1179, 10.1023/A:1008400706949 · doi:10.1023/a:1008400706949
  9. Semiglazov, 1994, Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer, Annals of Oncology, 5, 591, 10.1093/oxfordjournals.annonc.a058929 · doi:10.1093/oxfordjournals.annonc.a058929
  10. Cowan, 2003, Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial, Annals of Surgical Oncology, 10, 635, 10.1245/ASO.2003.12.008 · doi:10.1245/aso.2003.12.008
  11. Deo, 2003, Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0), Journal of Surgical Oncology, 84, 192, 10.1002/jso.10323 · doi:10.1002/jso.10323
  12. Hyams, 1993, An institutional experience with preoperative systematic chemotherapy in early stage breast cancer, Breast Cancer Research & Treatment, 27, 147 (Abstract 6
  13. Shao, 1999, Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis, Breast Cancer Research and Treatment, 53, 263, 10.1023/A:1006194921139 · doi:10.1023/a:1006194921139
  14. Stauffer, 1993, Preoperative versus postoperative adjuvant chemotherapy in early operable breast cancer, Breast Cancer Research & Treatment, 27, 148 (Abstract 1
  15. Felici, 2005, Taxanes as neoadjuvant chemotherapy for breast cancer: Pooled-analysis of 3120 patients enrolled in 10 randomized trials, J Clin Oncol ASCO Annual Meeting Proceedings, 16S, 682
  16. Fisher, 1989, A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors, New England Journal of Medicine, 320, 473, 10.1056/NEJM198902233200801 · doi:10.1056/nejm198902233200801
  17. Fisher, 1995, Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer, J Clin Oncol, 13, 537, 10.1200/JCO.1995.13.3.537 · doi:10.1200/jco.1995.13.3.537
  18. Fredriksson, 2003, Risk factors for local recurrence after breast-conserving surgery, Br J Surg, 90, 1093, 10.1002/bjs.4206 · doi:10.1002/bjs.4206
  19. Haagensen, 1943, Carcinoma of the breast. Criteria of inoperability, The American surgeon, 118, 859
  20. Haagensen, 1943, Carcinoma of the breast. Criteria of inoperability, The American surgeon, 118, 1032
  21. Hortobagyi, 1983, Multimodal treatment of locoregionally advanced breast cancer, Cancer, 51, 763, 10.1002/1097-0142(19830301)51:5<763::AID-CNCR2820510502>3.0.CO;2-C · doi:10.1002/1097-0142(19830301)51:5<763::aid-cncr2820510502>3.0.co;2-c
  22. Hortobagyi, 1997, Textbook of Breast Cancer: A Clinical Guide to Therapy, 155
  23. Jacquillat, 1989, Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients, Recent Results in Cancer Research, 115, 36, 10.1007/978-3-642-83337-3_6 · doi:10.1007/978-3-642-83337-3_6
  24. Perloff, 1982, Chemotherapy before and after mastectomy in stage III breast cancer, Archives of surgery, 117, 879, 10.1001/archsurg.1982.01380310005002 · doi:10.1001/archsurg.1982.01380310005002
  25. Segel, 1988, Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy, Radiology, 169, 49, 10.1148/radiology.169.1.3420282 · doi:10.1148/radiology.169.1.3420282
  26. Sharkey, 1996, Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma, Mod Pathol, 9, 893
  27. Veronesi, 1995, Conservation surgery after primary chemotherapy in large carcinomas of the breast, Ann Surg, 222, 612, 10.1097/00000658-199511000-00002 · doi:10.1097/00000658-199511000-00002
  28. Vinnicombe, 1996, Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation, Radiology, 198, 333, 10.1148/radiology.198.2.8596827 · doi:10.1148/radiology.198.2.8596827
  29. Wolff, 2000, Primary systemic therapy in operable breast cancer, J Clin Oncol, 18, 1558, 10.1200/JCO.2000.18.7.1558 · doi:10.1200/jco.2000.18.7.1558

Cited by

See all 407

Metadata

Authors
van der Hage, J. H., van de Velde, C. J., Mieog, S. J., & Charehbili, A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2007-04-18
Volume
2021
Issue
5
Pages
CD005002-CD005002
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2144713193
Cited by
407
References
53
FWCI
2.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preoperative chemotherapy for women with operable breast cancer. https://app.cochat.ai/papers/10.1002/14651858.cd005002.pub2
The paper
van der Hage, J. H., van de Velde, C. J., Mieog, S. J., & Charehbili, A. (2007). Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005002.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.